ReviewBritish journal of haematology2008
Cytotoxic T lymphocytes as immune-therapy in haematological practice.
Review in British journal of haematology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 36 citations in OpenAlex.
- Trial
- Use of Specific T Lymphocytes in Treating Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients: A Systematic Review.Pharmaceutics · 2024Review
- Advances in cellular and humoral immunotherapy - implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma.British journal of haematology · 2019Review
- Hematopoietic stem cell transplantation-50 years of evolution and future perspectives.Rambam Maimonides medical journal · 2014Article
- Optimizing the production of suspension cells using the G-Rex "M" series.Molecular therapy. Methods & clinical development · 2014Article
- Cellular immune therapy for viral infections in transplant patients.The Indian journal of medical research · 2013Review
- Other viral pneumonias: coronavirus, respiratory syncytial virus, adenovirus, hantavirus.Critical care clinics · 2013Review
- Differential outcome of neurological HCMV infection in two hematopoietic stem cell transplant recipients.BMC infectious diseases · 2012Article
- Article
- Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disorders.Clinical & developmental immunology · 2012Review
- Buffered memory: a hypothesis for the maintenance of functional, virus-specific CD8(+) T cells during cytomegalovirus infection.Immunologic research · 2011Review
- Strategies to harness immunity against infectious pathogens after haploidentical stem cell transplantation.American journal of translational research · 2011Article
- Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience.Cytotherapy · 2010Article
- CMV central nervous system disease in stem-cell transplant recipients: an increasing complication of drug-resistant CMV infection and protracted immunodeficiency.Bone marrow transplantation · 2010Review
- Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation.Expert opinion on biological therapy · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Viral infections are a significant cause of morbidity and mortality, particularly in pediatric allogeneic haematopoietic stem cell transplant recipients. Effective therapies are limited and often associated with significant side effects. Adoptive transfer of virus-reactive T cells offers a means of reconstituting antiviral immunity and this approach has been successfully used to prevent and treat cytomegalovirus, Epstein-Barr virus, and adenovirus infections in vivo. This review outlines the clinical trials that have been performed to date, and will describe future initiatives to (a) develop strategies that can increase the breadth of the viruses that can be targeted, and (b) simplify the process to extend this technology to more centers so that cellular therapy to reconstitute immunity can be more widely applied.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.